DE60234619D1 - Gene und proteine für verhinderung, vorhersage, prognose und therapie der herzgefäss-krankheit - Google Patents

Gene und proteine für verhinderung, vorhersage, prognose und therapie der herzgefäss-krankheit

Info

Publication number
DE60234619D1
DE60234619D1 DE60234619T DE60234619T DE60234619D1 DE 60234619 D1 DE60234619 D1 DE 60234619D1 DE 60234619 T DE60234619 T DE 60234619T DE 60234619 T DE60234619 T DE 60234619T DE 60234619 D1 DE60234619 D1 DE 60234619D1
Authority
DE
Germany
Prior art keywords
genes
prediction
prevention
forecast
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60234619T
Other languages
English (en)
Inventor
Marc Munnes
Mathias Gehrmann
Maresa Wick
Gerd Schmitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Siemens Healthcare Diagnostics GmbH Germany
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens Healthcare Diagnostics GmbH Germany filed Critical Siemens Healthcare Diagnostics GmbH Germany
Application granted granted Critical
Publication of DE60234619D1 publication Critical patent/DE60234619D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
DE60234619T 2001-10-08 2002-10-02 Gene und proteine für verhinderung, vorhersage, prognose und therapie der herzgefäss-krankheit Expired - Lifetime DE60234619D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124145.4A GB0124145D0 (en) 2001-10-08 2001-10-08 Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
PCT/EP2002/011034 WO2003031650A2 (en) 2001-10-08 2002-10-02 Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease

Publications (1)

Publication Number Publication Date
DE60234619D1 true DE60234619D1 (de) 2010-01-14

Family

ID=9923436

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60234619T Expired - Lifetime DE60234619D1 (de) 2001-10-08 2002-10-02 Gene und proteine für verhinderung, vorhersage, prognose und therapie der herzgefäss-krankheit

Country Status (6)

Country Link
EP (1) EP1436425B1 (de)
AT (1) ATE450622T1 (de)
AU (1) AU2002338852A1 (de)
DE (1) DE60234619D1 (de)
GB (1) GB0124145D0 (de)
WO (1) WO2003031650A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002332929A1 (en) 2001-09-07 2003-03-24 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor, hgprbmy39
EP1658379A2 (de) * 2003-08-29 2006-05-24 Integragen Menschliches obesität-suszeptibilitätsgen und verwendungen davon
EP1522857A1 (de) 2003-10-09 2005-04-13 Universiteit Maastricht Methode zur Feststellung des Risikos von Herzversagen in einem Individuum durch Bestimmung der Menge an Galectin-3 oder Thrombospondin-2
WO2005095641A1 (en) * 2004-03-03 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with mitogen-activated protein kinase kinase kinase 11 (map3k11)
US20110021433A1 (en) * 2004-10-04 2011-01-27 Harlan John M Methods for treating or preventing heart failure
CA2583004A1 (en) 2004-10-04 2006-04-20 University Of Washington Methods of inhibiting cell death or inflammation in a mammal
US8648045B2 (en) 2005-03-10 2014-02-11 Ben Gurion University Of The Negev Research And Development Authority Ltd. VDAC1 compositions and methods of use thereof for regulating apoptosis
EP2371846B1 (de) * 2005-03-10 2013-12-04 Ben Gurion University of the Negev Research and Development Authority Ltd. Zusammensetzungen des spannungsabhängigen anionenkanals (vdac1) und verfahren zu deren anwendung bei der regulierung der apoptose
WO2007043049A1 (en) * 2005-10-11 2007-04-19 Ben-Gurion University Of The Negev Research And Development Authority Compositions for silencing the expression of vdac1 and uses thereof
US8815519B2 (en) * 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases
US7550300B1 (en) * 2007-11-29 2009-06-23 Capgen Sciences, Inc. Prediction of bare metal stent restenosis
CA2739944A1 (en) * 2008-01-23 2009-07-30 Rigshospitalet Classification of individuals suffering from cardiovascular diseases according to survival prognoses as found by measuring the levels of biomarker ykl-40
WO2010037181A1 (en) * 2008-10-03 2010-04-08 The Walter And Eliza Hall Institute Of Medical Research Cell therapy and compositions therefor
US8672857B2 (en) 2009-08-25 2014-03-18 Bg Medicine, Inc. Galectin-3 and cardiac resynchronization therapy
WO2015011711A1 (en) 2013-07-25 2015-01-29 The National Institute for Biotechnology in the Negev Ltd. Short peptides derived from vdac1, compositions and methods of use thereof
SG10201912905VA (en) 2015-08-07 2020-02-27 Alx Oncology Inc Constructs having a sirp-alpha domain or variant thereof
WO2017081686A1 (en) 2015-11-10 2017-05-18 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Means and methods for reducing tumorigenicity of cancer stem cells
WO2019023347A1 (en) 2017-07-26 2019-01-31 Forty Seven, Inc. ANTI-SIRP-ALPHA ANTIBODIES AND ASSOCIATED METHODS
AU2020282791A1 (en) 2019-05-31 2021-12-09 ALX Oncology Inc. Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0495910B1 (de) * 1989-10-18 2001-09-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Herstellung und verwendung des menschlichen nm23-h2-proteins und dagegen gerichtete antikörper
GB0007268D0 (en) * 2000-03-24 2000-05-17 Cyclacel Ltd Cell cycle progression proteins

Also Published As

Publication number Publication date
EP1436425B1 (de) 2009-12-02
EP1436425A2 (de) 2004-07-14
AU2002338852A1 (en) 2003-04-22
ATE450622T1 (de) 2009-12-15
WO2003031650A2 (en) 2003-04-17
WO2003031650A3 (en) 2004-02-12
GB0124145D0 (en) 2001-11-28

Similar Documents

Publication Publication Date Title
DE60234619D1 (de) Gene und proteine für verhinderung, vorhersage, prognose und therapie der herzgefäss-krankheit
EP1900827A3 (de) Verfahren und Zusammensetzungen zur Vorhersage, Diagnose, Prognose, Verhinderung und Behandlung maligner Neoplasien
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
ME00425B (me) Liječenje sa anti-vegf antitijelima
WO2005047534A3 (en) Methods and compositions for the response prediction of malig-nant neoplasia to treatment
NO20052348L (no) Behandling av hemoragisk sjokk
EP2006298A3 (de) Jugendliches Hämochromatose-Gen (HFE2A), Expressionsprodukte und Verwendungen davon
WO2005119260A3 (en) Methods for predicting and monitoring response to cancer therapy
NO20076121L (no) Behandlinger for kardiovaskulaer sykdom
WO2002036771A3 (en) Imaging, diagnosis and treatment of disease
WO2001074853A3 (en) Methods and products for regulating cell motility
WO2004050907A3 (en) Method for determing predisposition to manifestation of immune system related diseases
NO20060781L (no) Anvendelse av loselig CD164 ved inflammatoriske og/eller autoimmune lidelser
WO2002012440A3 (en) Identifying drugs for and diagnosis of benign prostatic hyperplasia using gene expression profiles
TR200200278T2 (tr) Kalsilitik bileşimler
ATE367825T1 (de) Zusammensetzung und kit zur verwendung in der tumorbehandlung
WO2005108605A3 (en) Polymorphisms in abcb1 associated with a lack of clinical response to medicaments
WO2003027633A3 (en) Identifying drugs for and diagnosis of benign prostatic hyperplasia using gene expression profiles
IL169256A0 (en) Metalloprotease proteins
WO2002097127A3 (en) Genes and proteins for prevention, prediction, diagnosis, prognosis and treatment of chronic lung disease
ATE546548T1 (de) Verfahren zur prognose des nutzens einer antioxidationshemmenden therapie zur vorbeugung von herz-kreislauf-erkrankungen bei hyperglykämischen patienten
HK1057857A1 (en) Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof
WO2002090991A3 (en) Proteins and genes for diagnosis and treatment of erbb2-related cancer
ATE341323T1 (de) Verwendung von darifenacin zur behandlung des harndrangs
EP1293570A3 (de) Verwendung des Aprataxin Gens zur Diagnose und Behandlung der früheinsetzenden Hinterstrangataxie (EAOH - early-onset spinocerebellar ataxia)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition